Business Context and Reporting Period
Company: BiondVax Pharmaceuticals Ltd. (Note: Input metadata referenced "Scinai Immunotherapeutics," but the filing text identifies the registrant as BiondVax Pharmaceuticals Ltd.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Accounting Standard: International Financial Reporting Standards (IFRS)
Reporting Currency: New Israeli Shekels (NIS), with USD translations provided at a rate of 3.845 NIS to $1.00.
BiondVax is a clinical-stage biopharmaceutical company incorporated in Israel, focused on developing M-001, a synthetic peptide-based universal influenza vaccine. The company has no approved products and has not generated any revenue to date. Its primary activities involve research and development (R&D) and clinical trials for M-001, which is currently in Phase 2 development for three indications: Universal Standalone, Universal Seasonal Primer for Elderly, and Universal Pandemic Primer.
Key Financial Metrics
| Financial Metric (Year Ended Dec 31, 2016) | NIS (in thousands) | USD (in thousands) |
|---|---|---|
| Revenue | 0 | 0 |
| Research & Development Expenses (Gross) | 9,397 | 2,444 |
| R&D Expenses (Net of Grants) | 7,794 | 2,027 |
| Marketing, General & Administrative Expenses | 4,106 | 1,068 |
| Operating Loss | 11,900 | 3,095 |
| Net Loss | 9,184 | 2,389 |
| Cash and Cash Equivalents | 15,705 | 4,084 |
| Short-term Deposits & Marketable Securities | 9,619 | 2,502 |
| Total Liquid Assets | 25,324 | 6,586 |
| Total Assets | 30,110 | 7,830 |
| Total Liabilities | 4,494 | 1,168 |
| Shareholders' Equity | 25,616 | 6,662 |
| Accumulated Deficit | ~88,000 (approx) | ~23,112 |
Note: The filing states an accumulated deficit of approximately $23,112 thousand as of December 31, 2016. The NIS equivalent is not explicitly stated in the summary table but is derived from the USD figure.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased to NIS 9.2 million ($2.4 million) in 2016 from NIS 10.2 million ($2.6 million) in 2015. This improvement was primarily driven by a decrease in gross R&D expenses (NIS 9.4 million in 2016 vs. NIS 10.7 million in 2015) due to lower subcontractor costs following the 2015 cGMP audit preparation.
- Operating Expenses: Marketing, general, and administrative (MG&A) expenses increased to NIS 4.1 million ($1.1 million) in 2016 from NIS 3.4 million ($0.9 million) in 2015, attributed to higher professional services and salary expenses.
- Financial Income: Net financial income increased significantly to NIS 2.7 million ($0.7 million) in 2016 compared to NIS 1.1 million ($0.3 million) in 2015, largely due to favorable exchange differences on cash equivalents and the revaluation of options.
- Liquidity: Total liquid assets (cash, short-term deposits, and marketable securities) decreased from approximately NIS 37.5 million ($9.6 million) in 2015 to NIS 27.4 million ($7.1 million) in 2016, reflecting the utilization of cash to fund operations.
Guidance, Outlook, and Risks
Outlook and Capital Requirements
Management estimates that as of December 31, 2016, the company had sufficient cash and commitments to fund operations for at least 15 months without raising additional capital. The company expects to continue incurring substantial losses for the foreseeable future. Future capital requirements depend on the scope and progress of clinical trials, regulatory approvals, and commercialization efforts.
Key Developments
- Clinical Trials: The company completed the BVX-007 Phase 2 trial in Europe in September 2016 with positive preliminary safety results. It plans to participate in a Phase 2 trial in the U.S. with the NIAID in 2017.
- Manufacturing: On March 28, 2017, the company received approval for a grant representing 20% of a NIS 20 million budget to construct a mid-sized factory in Jerusalem for Phase 3 and commercial production.
- Financing: In January 2017, the company entered into an investment agreement with Angels High Tech Investments Ltd. for approximately $2.83 million in exchange for ordinary shares. An "At-The-Market" (ATM) issuance program was also established in November 2016.
Risks and Contingencies
- Profitability: The company has a history of operating losses and may never become profitable. Success depends entirely on the regulatory approval and commercialization of M-001.
- Regulatory Approval: There is no assurance that the FDA or other authorities will approve Phase 3 clinical trials or the product itself. Failure to obtain approval would materially reduce the target market.
- Intellectual Property: The company relies on an exclusive license from Yeda Research and Development Company Ltd. Termination of this license would have a material adverse effect.
- Legal Proceedings: The company is a defendant in a lawsuit regarding the cancellation of a consulting agreement, seeking approximately NIS 1.5 million ($380,000). Management believes this will not pose a material financial burden.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political, economic, and military instability.
Important Facts for Investor Verification
- Cash Runway: Verify the current cash balance and burn rate to confirm the "15 months" runway estimate remains valid given the passage of time since the 2016 year-end.
- Phase 2 Trial Results: Confirm the final immunogenicity results of the BVX-007 trial (expected Q2 2017) and the status of the planned NIAID Phase 2 trial in the U.S.
- Manufacturing Grant Conditions: Review the specific terms and conditions of the NIS 20 million grant for the Jerusalem factory, including the requirement to finance 80% of the cost and the 10-year commitment to maintain IP and manufacturing in Israel.
- Capital Raising: Monitor the utilization of the ATM program and the status of the $2.83 million investment from Angels High Tech Investments to ensure sufficient funding for Phase 3 trials.
- Yeda License Status: Confirm there are no disputes or breaches regarding the exclusive license agreement with Yeda, which is critical to the company's core technology.